Free tool
FAERS Monitor: Stivarga
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204369 or its brand name (Stivarga, Regorafenib). Reports on generic versions are filed under their own applications.
Reports
11,611
Serious
10,468
90% of reports
Hospitalization
4,066
Death reported
2,373
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,080
- fatigue1,778
- palmar-plantar erythrodysaesthesia syndrome1,446
- diarrhoea1,427
- decreased appetite1,097
- death1,007
- asthenia950
- dysphonia825
- nausea818
- pain in extremity774
- pyrexia757
- hypertension700
- weight decreased639
- vomiting575
- rash561
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 119 |
| 2013 | 928 |
| 2014 | 810 |
| 2015 | 886 |
| 2016 | 653 |
| 2017 | 1,019 |
| 2018 | 1,150 |
| 2019 | 980 |
| 2020 | 962 |
| 2021 | 956 |
| 2022 | 870 |
| 2023 | 770 |
| 2024 | 694 |
| 2025 | 567 |
| 2026 | 245 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,548 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| palmar-plantar erythrodysaesthesia syndromeSignal | 1,446 | 119.7 | 113.9 | 159,747 |
| dysphoniaSignal | 825 | 25.9 | 24.2 | 19,502 |
| decreased appetiteSignal | 1,097 | 8.6 | 8.1 | 7,398 |
| hypertensionSignal | 700 | 6.0 | 5.6 | 2,934 |
| pain in extremitySignal | 774 | 4.8 | 4.5 | 2,328 |
| astheniaSignal | 950 | 4.6 | 4.3 | 2,702 |
| off label useSignal | 2,080 | 4.3 | 4.1 | 5,502 |
| weight decreasedSignal | 639 | 4.2 | 3.9 | 1,544 |
| fatigueSignal | 1,778 | 4.1 | 4.0 | 4,391 |
| diarrhoeaSignal | 1,427 | 4.0 | 3.8 | 3,317 |
| pyrexiaSignal | 757 | 4.0 | 3.7 | 1,703 |
| rashSignal | 561 | 2.3 | 2.2 | 434 |
| vomitingSignal | 575 | 2.2 | 2.0 | 391 |
| deathSignal | 1,007 | 2.1 | 2.0 | 618 |
| nausea | 818 | 1.9 | 1.8 | 345 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.